The European Association of Urology recommends offering PSA based prostate cancer screening to men with cancer-predisposing BRCA2 variants who have been counselled on the potential risks and benefits of screening from the age of 40 although they do not specify a screening interval(24). Here, BRCA2 is linked to prostate carcinoma.